Abstract：Objective: To investigate the prognostic value of hematuria in patients with stage T1-T2 renal cell carcinoma. Methods: The clinical data of 1 352 T1a-T2b renal cancer patients who underwent surgery from 2010 to 2012 were retrospectively analyzed. Student T-test and ANOVA were used to compare the clinicopathological data of two groups in terms of hematuria. The single factor and multiple factor regression analyses were used to analyze the probability of hematuria as an independent prognostic factor for renal cell carcinoma. Results: The incidence of hematuria in 1 352 cases of renal cell carcinoma was 11%. The clinical stage and Furhman nuclear grade in hematuria group were higher than those in normal group. The 5-year disease-free survival rates in hematuria group and normal group were 84.3% and 92.9%, respectively, with significant difference between the two groups (P<0.01). Cox regression analysis showed that hematuria, TNM stage, and Furhman grade were independent prognostic factors for T1-T2 localized renal cell carcinoma. Conclusions: Hematuria can be used as an effective indicator of the prognosis of patients with locally advanced stage T1-T2 renal cell carcinoma.
[1] Capitanio U, Montorsi F.Renal cancer. Lancet, 2016,387(10021):894-906.
[2] 徐虎,王福利,袁建林.肾癌患者后腹腔镜下肾部分切除术的预后相关因素分析.中华泌尿外科杂志,2017,38(8):591-594.
[3] Krejci KG, Blute ML, Cheville JC, et al.Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome. Urology, 2003,62(4):641-646.
[4] Jung H, Gleason JM, Loo RK, et al.Association of hematuria on microscopic urinalysis and risk of urinary tract cancer. J Urol, 2011,185(5):1698-1703.
[5] Thompson IM.The evaluation of microscopic hematuria: a population-based study. J Urol, 1987,138(5):1189-1190.
[6] Cao Y, Fan Y, Chen Y, et al.Gross hematuria is more common in male and older patients with renal tuberculosis in China: a Single-Center 15-Year clinical experience. Urol Int, 2017,99(3):290-296.
[7] Sharp VJ, Barnes KT, Erickson BA.Assessment of asymptomatic microscopic hematuria in adults. Am Fam Physician, 2013,88(11):747-754.
[8] Watanabe D, Horiguchi A, Tasaki S, et al.Impact of body mass index on clinicopathological outcomes in patients with renal cell carcinoma without anorexia-cachexia syndrome. Mol Clin Oncol, 2018,8(1):47-53.
[9] 范敏,徐仁芳,陆皓,等.术前C反应蛋白/白蛋白比值在预测肾透明细胞癌患者预后方面的价值.中华泌尿外科杂志,2017,38(12):918-922.
[10] Schiavina R, Borghesi M, Chessa F, et al.[Predictors of positive surgical margins after nephron-sparing surgery for renal cell carcinoma: retrospective analysis on 298 consecutive patients]. Urologia, 2014,81(1):40-45.
[11] Templeton AJ, Knox JJ, Lin X, et al.Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol, 2016,70(2):358-364.
[12] Velis JM, Ancizu FJ, Hevia M, et al.Risk models for patients with localised renal cell carcinoma. Actas Urol Esp, 2017,41(9):564-570.
[13] Rodríguez A, Patard JJ, Lobel B.Renal cell carcinoma in young adults: incidence, disease outcome and review of the literature. Arch Esp Urol, 2002,55(8):969-975.
[14] 张旭,李宏召.腹腔镜下保留肾单位手术治疗肾肿瘤现状.中华泌尿外科杂志,2007,28(7):437-438.
